Obesity Treatment Articles & Analysis
15 news found
Obesity is a metabolic condition resulting from an imbalance between the energy consumed and the energy expended. ...
Dr. Ali Tinazli is the CEO of lifespin.health and has 15+ years in Fortune 100 corporate strategy and entrepreneurship (SONY, HP). Obesity rates continue to climb alongside a $254.9 billion global weight loss products and services market. Supplements, smartphone weight loss apps, diet plans and exercise programs are widely available to consumers, yet the World Obesity Federation projects that 1 ...
“FDA clearance of our GIBI HD™ calibration tube, which supports bariatric procedures across the spectrum, marks an important addition to our suite of physician led weight loss solutions and we look forward to formally introducing this important new product at the International Federation for the Surgery of Obesity and Metabolic Disorders – IFSO 2022 World ...
About ReShape Lifesciences™ ReShape Lifesciences™ is America's premier weight loss and metabolic health-solutions company, offering an integrated portfolio of proven products and services that manage and treat obesity and metabolic disease. The FDA-approved Lap-Band® Program provides minimally invasive, long-term treatment of ...
Pemvidutide is an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH. Details for the oral presentation are as follows: Title: Pemvidutide (ALT-801), a novel GLP-1/Glucagon Dual Receptor Agonist, Achieves Rapid and Potent Reductions in Body Weight and Liver Fat: Results of a Placebo-Controlled, ...
About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of ...
(Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that the results of the Company's recently completed Phase 1 clinical trial of pemvidutide, an investigational GLP-1/glucagon dual receptor agonist in development for the treatment of obesity and NASH, will be presented in an oral presentation at the 82nd American Diabetes Association ...
His presentation will provide an overview of pemvidutide, the Company’s novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of obesity and NASH. Dr. Harris will also moderate a panel discussion on clinical endpoints in NASH trials. Details for the oral presentation are as follows: Title: The Emerging Weight Loss ...
About Altimmune Altimmune is a clinical-stage biopharmaceutical company focused on the development of novel peptide-based therapeutics for the treatment of obesity and liver diseases. The company’s lead product candidate, pemvidutide (ALT-801), is a GLP-1/glucagon dual receptor agonist that is being developed for the treatment of ...
(Nasdaq: ALT), a clinical-stage biopharmaceutical company, today announced that it has enrolled the first subject in the 48-week Phase 2 MOMENTUM trial evaluating the safety and efficacy of pemvidutide1 in subjects with obesity or overweight. Pemvidutide is a novel, investigational GLP-1/glucagon dual receptor agonist under development for the treatment of ...
With the addition of Adam’s medicinal chemistry expertise and his rich knowledge of small molecule drug discovery and R&D and Fez’s keen insights and business acumen for deals and partnerships, grounded in his medicinal chemistry background, we have the right mix of skills and perspectives on the leadership team that will help us bridge the gap between drug discovery and ...
Neurovalens, a global leader of neuro-technology products, is embarking on the development of a device for the treatment of obesity with £1m support from Invest NI. The technology is based on the neuro stimulation of specific areas of the brain responsible for influencing appetite and cravings. The company specialises in combining neuroscience and ...
(Nasdaq: RYTM), a biopharmaceutical company aimed at developing and commercializing therapies for the treatment of rare genetic diseases of obesity, today announced an exclusive licensing agreement for the development and commercialization of IMCIVREE® (setmelanotide) in Greater China, including mainland China, Hong Kong and Macau. ...
“We are impressed by data from the ReShape clinical trial and look forward to working with the company’s experienced management team to fill the sizeable, unaddressed need in the global obesity market with this new treatment option.” The ReShape Integrated Dual Balloon System was evaluated in the REDUCE pivotal trial, the results of which were ...
While an estimated 50 million Americans are classified as obese with a BMI of 30-40, many neither qualify for nor want surgery, creating a significant unmet need for additional treatment options. Obesity is a major risk factor for serious health complications, many of which are the leading causes of preventable death, including heart disease, ...